Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.86)
# 71
Out of 5,133 analysts
29
Total ratings
76%
Success rate
47.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $4.92 | +387.80% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $10.14 | +116.96% | 1 | Jan 7, 2026 | |
| ERAS Erasca | Initiates: Overweight | $5 | $7.51 | -33.38% | 1 | Jan 7, 2026 | |
| BDTX Black Diamond Therapeutics | Assumes: Overweight | $9 | $2.75 | +227.27% | 1 | Nov 18, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $10.59 | +145.51% | 1 | Nov 5, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $112 → $128 | $101.17 | +26.52% | 4 | Oct 27, 2025 | |
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $16.81 | +24.93% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $13.79 | +204.57% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $119.95 | -37.47% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $19.83 | +81.54% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $52.58 | +4.60% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $11 | $10.44 | +5.36% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $17.53 | +105.36% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.15 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.74 | +191.97% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.75 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $66.75 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $22.57 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.35 | - | 1 | Oct 31, 2022 |
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $4.92
Upside: +387.80%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $10.14
Upside: +116.96%
Erasca
Jan 7, 2026
Initiates: Overweight
Price Target: $5
Current: $7.51
Upside: -33.38%
Black Diamond Therapeutics
Nov 18, 2025
Assumes: Overweight
Price Target: $9
Current: $2.75
Upside: +227.27%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $10.59
Upside: +145.51%
Nuvalent
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $101.17
Upside: +26.52%
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $16.81
Upside: +24.93%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $13.79
Upside: +204.57%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $119.95
Upside: -37.47%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $19.83
Upside: +81.54%
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $52.58
Upside: +4.60%
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $10.44
Upside: +5.36%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $17.53
Upside: +105.36%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.15
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.74
Upside: +191.97%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.75
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $66.75
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $22.57
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.35
Upside: -